FilingReader Intelligence
Amoytop Biotech gets approval for growth hormone trials
August 21, 2025 at 01:30 PM UTC•By FilingReader AI
Xiamen Amoytop Biotech received approval to conduct clinical trials for its growth hormone Yipeisheng in treating Adult Growth Hormone Deficiency.
The drug was initially approved in May 2025 for treating growth hormone deficiency in children aged three and above.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SSE:688278•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Xiamen Amoytop Biotech publishes news
Free account required • Unsubscribe anytime